Devonian reports additional molecular data from MASH liver study

Executive Summary

• Devonian Health Group announced additional pre‑clinical gene expression results from its STAM™ mouse model of metabolic dysfunction‑associated steatohepatitis (MASH), confirming dose‑dependent anti‑inflammatory and anti‑fibrotic effects of Thykamine™.
• At the highest tested dose (50 mg/kg), Thykamine™ markedly down‑regulated 29 fibrosis‑ and inflammation‑related genes, with several showing 80–90% reductions versus placebo.
• The data provide molecular mechanistic support for previously reported histological improvements and will be included in a forthcoming scientific publication.

Key Details

• Study Design: Oral Thykamine™ administered once daily for three weeks at 0.5 mg/kg, 5.0 mg/kg, and 50.0 mg/kg to STAM™ mice; placebo control group included.
• Gene Panel: 29 genes examined – 13 fibrosis‑related, 5 inflammation‑related, 11 involved in both pathways.
• Top Down‑regulated Fibrosis Genes (max dose): CCN1, CCN2, COL1A1, COL1A2, COL5A2, JAG1, MMP2, MMP13, SERPINE1, SERPINE2, SNAI1, TGFBR1.
• Top Down‑regulated Inflammation Genes (max dose): CCL2, CCR2, IFNG, MMO8.
• Dual‑role Genes Modulated: COL3A1, COL6A1, FN1, TGFB1, TIMP1, MMP14, TNF, IL10, TLR4.
• Magnitude of Effect: Several genes exhibited 80–90% reduction relative to placebo at 50 mg/kg.
• Dose‑Response: Consistent, progressive down‑regulation across low, mid, and high dose groups, indicating pharmacologic activity.
• Regional Variation: Gene expression differed between caudal and lateral liver lobes, suggesting heterogeneous intra‑hepatic activity.
• Analytical Methods: PCR performed by Dr. Louis Flamand (Université Laval); statistical analysis by Dr. John Sampalis (McGill University).
• CEO Comment: “We are delighted to share these gene expression results… The data demonstrate that Thykamine™ modulates multiple genes involved in fibrosis and inflammation, reinforcing its potential to target underlying disease pathology and prevent progression of MASH.” – Dr. André P. Boulet, CEO.

Notable Quotes

• “This study further adds to the growing body of evidence supporting Thykamine™'s multi‑targeting mode of action… results strengthen Thykamine™'s positioning across a broad array of inflammatory diseases, now including hepatic conditions alongside dermatology and Inflammatory Bowel Disease.” – Dr. André P. Boulet, CEO.